Pooled Results of VP-102 Safety and Efficacy in Phase 3 Trials for Molluscum Contagiosum by Fitzpatrick Skin Type (FST)
Main Article Content
Keywords
VP-102, phase 3 trial, molluscum contagiosum, safety, efficacy
Abstract
N/A
References
1. Ware O et.al. Racial Limitations of Fitzpatrick Skin Type. Cutis. 2020;105: 77-80.
2. Eichenfield L et.al. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device
Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021. Mar;22(2): 257-265.
2. Eichenfield L et.al. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device
Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021. Mar;22(2): 257-265.